Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler

International Journal of Nanomedicine

Volumn 6, Issue , 2011, Pages 311-320

  Salem, H F ^a   Abdelrahim, M E ^b   Abo Eid, K ^c   Sharaf, M A ^c,d  

^a BENI SUEF UNIVERSITY   (Egypt)

^b Beni Suef University   (Egypt)

^c Helwan University   (Egypt)

^d The American University in Cairo   (Egypt)

Author keywords

Agglomerates; Dry powder inhaler; Nanoparticles; Theophylline

Indexed keywords

NANOROD; STEARIC ACID; THEOPHYLLINE; BRONCHODILATING AGENT; NANOPARTICLE; NANOTUBE; SODIUM CHLORIDE;

ANGLE OF REPOSE; ARTICLE; BULK DENSITY; DISPERSITY; DRUG FORMULATION; DRUG SOLUBILITY; HAUSNER RATIO; PARTICLE SIZE; TAPPED DENSITY; ZETA POTENTIAL; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; KINETICS; METHODOLOGY; PH; POWDER; POWDER INHALER; ULTRASTRUCTURE;

BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HYDROGEN-ION CONCENTRATION; KINETICS; NANOPARTICLES; NANOTUBES; PARTICLE SIZE; POWDERS; SODIUM CHLORIDE; THEOPHYLLINE;

EID: 79959525561     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14309     Document Type: Article

References (60)

1. Geller D. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50(10): 1313-1321.
2. Rau J. The inhalation of drugs: Advantages and problems. Respir Care. 2005;50(3):367-382.
3. Pauwels R, Lofdahl C, Postma D, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997; 337(20):1405-1411.
4. Telko M, Hickey A. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-1227.
5. Taburet A, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet. 1994;26(5):396-418.
6. Markham A, Faulds D. Theophylline: A review of its potential steroid sparing effects in asthma. Drugs. 1998;56(6):1081-1091.
7. Mokra D, Drgova A, Mokry J, et al. Combination of budesonide and aminophylline diminished acute lung injury in animal model of meconium aspiration syndrome. J Physiol Pharmacol. 2008;59 Suppl 6: 461-471.
8. Barnes PJ, Peter JB, Ian WR, Neil CT. Theophylline. In: Barnes PJ, Rodger IW, Thomson NC, editors. Asthma: Basic Mechanisms and Clinical Management. 3rd ed. London: Academic Press; 1998.
9. Shen DD, Fixley M, Azarnoff DL. Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci. 1978;67(7):916-919.
10. Koizumi S, Saito K, Murashima Y, Kawakami Y. Theophylline-induced changes in mouse electroencephalograms. Brain Dev. 2010; 32(10):818-820.
11. Nadai M, Kato M, Yasui K, et al. Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats. Biol Pharm Bull. 2007;30(3):562-568.
12. Yang KH, Lee JH, Lee MG. Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: Involvement of CYP1A1/2 in the formation of 1,3-DMU. J Pharm Pharmacol. 2008;60(1):45-53.
13. Choi HD, Kang HE, Chung HJ, Bae SK, Shin KN, Lee MG. Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats. Biopharm Drug Dispos. 2007;28(8): 445-454.
14. Hendeles L, Weinberger M, Johnson G. Monitoring serum theophylline levels. Clin Pharmacokinet. 1978;3(4):294-312.
15. Barnes PJ. Theophylline for COPD. Thorax. 2006;61(9):742-744.
16. Jacobs M, Senior R, Kessler G. Clinical experience with theophylline: Relationships between dosage, serum concentration, and toxicity. JAMA. 1976;235(18):1983-1986.
17. Hendeles L, Iafrate RP, Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet. 1984;9(2):95-135.
18. Owen J, Nakatsu K. Spectrophotometry of theophylline-7-acetic acid and theophylline. Clin Chem. 1978;24(2):367-368.
19. Benita S, Donbrow M. Release kinetics of sparingly soluble drugs from ethyl cellulose-walled microcapsules: Theophylline microcapsules. J Pharm Pharmacol. 1982;34(2):77-82.
20. Schulz HU, Steinijans VW, Gabel H. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing. Int J Clin PharmacolTher Toxicol. 1984;22(11):621-625.
21. Hart S. Should aminophylline be abandoned in the treatment of acute asthma in adults? QJM. 2000;93(11):761-765.
22. Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam Clin Pharmacol. 2010;24(5):595-605.
23. Zacarias EC, Castro AA, Cendon S. Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: A systematic review. J Bras Pneumol. 2007;33(2):152-160. Spanish.
24. Ellis E, Koysooko R, Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics. 1976;58(4):542-547.
25. Braat M, Jonkers R, Bel E, van Boxtel C. Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. Clin Pharmacokinet. 1992;22(3):231-237.
26. Marriott C, MacRitchie HB, Zeng XM, Martin GP. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations. Int J Pharm. 2006;326(1-2):39-49.
27. Zeng XM, MacRitchie HB, Marriott C, Martin GP. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations. Pharm Res. 2006;23(9):2200-2209.
28. Edwards D, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;85(2):379-385.
29. Plumley C, Gorman E, El-Gendy N, Bybee C, Munson E, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm. 2009;369(1-2):136-143.
30. Zhao H, Le Y, Liu H, et al. Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI). Powder Technol. 2009;194(1-2):81-86.
31. Sweeney L, Wang Z, Loebenberg R, Wong J, Lange C, Finlay W. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm. 2005;305(1-2):180-185.
32. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics. Int J Nanomedicine. 2007;2(4):675-688.
33. Morice A, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract. 2007; 61(11):1874-1883.
34. European Pharmacopoeia. 2.9.18. Preparations for inhalation: Aerodynamic assessment of fine particles. Strasbourg, France: Council of Europe; 2002.
35. British Pharmacopoeia. Preparations for inhalation. Aerodynamic assessment of fine particles-fine particle dose and particle size distribution (Ph. Eur. method 2.9.18). London: British Pharmacopoeia; 2005.
36. United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. United States Pharmacopeia and National Formulary; 2005.
37. Atia NN, York P, Clark BJ. Development and validation of a rapid and efficient method for simultaneous determination of methylxanthines and their metabolites in urine using monolithic HPLC columns. J Sep Sci. 2009;32(7):931-938.
38. Copley. Copley Scientific Catalogue. Available from: http://www.copleyscientific.co.uk/new/inhaler%20brochure%202006%20(hi%20 res).pdf. Accessed December 16, 2006.
39. Van Oort M. In vitro testing of dry powder inhalers. AerosolSciTechnol. 1995;22(4):364-373.
40. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: A new class of particles for controlled and modulated pulmonary drug delivery. J Control Release. 2003;93(1):15-28.
41. Bhavane R, Karathanasis E, Annapragada AV. Triggered release of ciprofloxacin from nanostructured agglomerated vesicles. Int J Nanomedicine. 2007;2(3):407-418.
42. Bailey M, Gorman E, Munson E, Berkland C. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir. 2008;24(23): 13614-13620.
43. Puechagut H, Bianchotti J, Chiale C. Preparation of norfloxacin spherical agglomerates using the ammonia diffusion system. J Pharm Sci. 1998;87(4):519-523.
44. Bailey M, Berkland C. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29(1):196-212.
45. Matteucci M, Hotze M, Johnston K, Williams R IIIrd. Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir. 2006;22(21):8951-8959.
46. Rasenack N, Steckel H, Müller B. Micronization of anti inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci. 2003;92(1):35-44.
47. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech. 2008;9(3):755-761.
48. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J Control Release. 2005;107(3):387-394.
49. Mizoe T, Ozeki T, Okada H. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J Control Release. 2007;122(1):10-15.
50. Salem H. Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. Int J Nanomedicine. 2010;5:943-954.
51. Shi L, Plumley C, Berkland C. Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir. 2007;23(22): 10897-10901.
52. Chow A, Tong H, Chattopadhyay P, Shekunov B. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411-437.
53. Patil G, Matthews R, Cornwell D. Effect of ionization and cation selectivity on the expansion of stearic acid monolayers. J Lipid Res. 1972;13(5):574-579.
54. Patil G, Dorman N, Cornwell D. Effects of ionization and counterion binding on the surface areas of phosphatidic acids in monolayers. J Lipid Res. 1979;20(5):663-668.
55. Kumon M, Machida S, Suzuki M, Kusai A, Yonemochi E, Terada K. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate. Chem Pharm Bull. 2008;56(5):617-625.
56. Nokhodchi A, Okwudarue ON, Valizadeh H, Momin MN. Cogrinding as a tool to produce sustained release behavior for theophylline particles containing magnesium stearate. AAPS PharmSciTech. 2009; 10(4):1243-1251.
57. Fults K, Miller I, Hickey A. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol. 1997;2(1):67-79.
58. Riddick T. Control of colloid stability through zeta potential: With a closing chapter on its relationship to cardiovascular disease, 1968. Available from: http://www.hbci.com/∼wenonah/riddick/chap22.htm. Accessed on January 11, 2011.
59. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: An observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3): 249-254.
60. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735-1742.